Adjuvant and neoadjuvant treatment of breast cancer

Seminars in Oncology

Volumn 28, Issue 1, 2001, Pages 13-29

  Gianni, Luca ^a   Valagussa, Pinuccia ^a   Zambetti, Milvia ^a   Moliterni, Angela ^a   Capri, Giuseppe ^a   Bonadonna, Gianni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONSERVATIVE TREATMENT; DRUG MEGADOSE; HUMAN; LEUKEMIA; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT PLANNING;

EID: 0035117337     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90042-9     Document Type: Article

References (58)

1. The results of radical operation for the cure of carcinoma of the breast
2. Personal contributions to the progress in breast cancer research and treatment
3. A role for chemotherapy as an adjuvant to surgery
4. Concepts for systemic treatment of micrometastases
5. L-phenylanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings
6. Combination chemotherapy as an adjuvant treatment in operable breast cancer
7. Evolving concepts in the systemic adjuvant treatment of breast cancer
8. Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women
9. Tamoxifen for early breast cancer: An overview of the randomised trials
10. Polychemotherapy for early breast cancer: An overview of randomised trials
11. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up
12. Dose-response effect of adjuvant chemotherapy in breast cancer
13. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
14. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node negative and estrogen receptor-negative breast cancer. Updated results
15. Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles
16. Advantage of an Adriamycin combination plus halotestin after initial cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) for adjuvant therapy of node-positive stage II breast cancer
17. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes
18. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results
19. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer
20. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non-responsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
21. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
22. Carcinogenic effects of cancer treatment
23. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
24. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
25. Tamoxifen (T) versus cyclophosphamide, Adriamycin, and 5-FU plus either concurrent or sequential T in postmenopausal receptor(+), node (+) breast cancer: A Southwest Oncology Group phase III intergroup trial
26. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: Findings from NSABP B-22
27. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines
28. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma
29. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more axillary nodes involved. Five years results
30. Lack of efficacy of adjuvant high-dose tandem combination chemotherapy for high-risk primary breast cancer - A randomized trial
31. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/ NCIC MA-13
32. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy
33. Randomized, controlled trial of high dose chemotherapy (HD-CNVp) vs standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer
34. Effects of radiotherapy and surgery in early breast cancer: An overview of randomized trials
35. Effects of surgery on the cell kinetics of residual tumor
36. Effect of surgical removal on the growth and kinetics of residual tumor
37. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases
38. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate
39. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
40. Multidisciplinary management of advanced primary and metastatic breast cancer
41. Primary chemotherapy in operable breast cancer
42. Effect of preoperative chemotherapy in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
43. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
44. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute
45. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer
46. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
47. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer
48. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
49. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
50. Current and future trends in the multidisciplinary approach for high-risk breast cancer: The experience of the Milan Cancer Institute
51. Long-term side effects from systemic drug therapy
52. Introduction to the study of multiple primary cancer
53. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
54. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy and breast irradiation
55. Effects if cancer chemotherapy on gonadal function and reproductive capacity
56. Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively
57. Paclitaxel by 3-hour in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study